Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Where To Buy Pirfenidone"

23:06 EDT 25th July 2014 | BioPortfolio

Matching Channels


Matching News

Pirfenidone and Fibrocyte Accumulation in Pulmonary Fibrosis

Does pirfenidone inhibit fibrocyte pool size in the lungs of bleomycin-treated mice? Respiratory Research

Inhaled Pirfenidone Shows Promise in Lung Fibrosis

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs. Martin Kolb and Kjetil Ask at McMaster University announced additional measured advantages of inha...

InterMune ASCENDs on new Phase III pirfenidone data

Brisbane, California-based InterMune's stock soared 170.8% higher on 25 February to close at $37.80 per share with a $3bn market cap after the company said pirfenidone cut the percentage of IPF patien...

InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)

BRISBANE, Calif., Feb. 25, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that top-line data from ASCEND, a Phase 3 trial evaluating pirfenidone in patients with idiopa...

Genoa's Inhaled Pirfenidone Shows Potential in Lung Fibrosis

Genoa Pharmaceuticals and collaborators Martin Kolb and Kjetil Ask at McMaster University announced additional measured advantages of inhaled GP-101 (aerosol pirfenidone) in the treatment of idiopathi...

US breakthrough status for InterMune’s pirfenidone

US biotech firm InterMune’s Esbriet (pirfenidone) has been granted Breakthrough Therapy designation from the US Food and Drug Administration. The announcement of Friday caused a 2.7% rise to $41.70...

FDA Grants breakthough therapy designation for InterMune’s pirfenidone

InterMune has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for its pirfenidone, an investigational treatment for adult patients with idiopathic pulmonary fi...

FDA accepts NDA for InterMune's pirfenidone

FDA accepted for review a resubmitted NDA from InterMune Inc. (NASDAQ:ITMN) for pirfenidone to treat idiopathic pulmonary fibrosis (IPF). The agency designated the NDA a Class 2 resubmission, with a N...

Matching PubMed Articles

Antifibrotic Effect of Pirfenidone on Human Pterygium Fibroblasts.

Abstract Objective: The effects of pirfenidone were investigated on cultured human pterygium fibroblasts (HPFs). Methods: HPFs were obtained from pterygium surgery and subjected to primary culture. Af...

Pirfenidone attenuates the IL-1β-induced hyaluronic acid increase in orbital fibroblasts from patients with thyroid-associated ophthalmopathy.

Purpose:This study aimed to investigate the effect of pirfenidone on the interleukin (IL)-1β-induced hyaluronic acid (HA) increase in orbital fibroblasts from patients with thyroid-associated ophthal...

Pirfenidone: an update on clinical trial data and insights from everyday practice.

Pirfenidone is an orally active, small molecule that inhibits synthesis of profibrotic and inflammatory mediators. It was approved for the treatment of adults with mild-to-moderate idiopathic pulmonar...

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events.

Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free...

Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Pirfenidone, an oral anti-inflammatory, antifibrotic agent with activity in idiopathic pulmonary fibrosis, may mediate anti-tumor activity in neurofibromatosis type 1 (NF1) and plexiform neurofibromas...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement